Clinical Trial

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

Study acronym: SIDEC
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
SIDEC - (Subcutaneous Immunoglobulin in De-novo CIDP) ia a study designed as a randomized, parallel study with an open-label extension phase. The aims are to compare the effect of SCIG and IVIG in 60 treatment-naïve CIDP patients, and to detect the lowest effective dosage for maintenance treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-10-09.
Trial Details
NCT Number NCT04589299
Lead Sponsor University of Aarhus
Collaborators: Rigshospitalet, Denmark, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital
Conditions CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 60 participants
Start Date 2020-06-04
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-17